Literature DB >> 22976128

Imatinib-dependent tyrosine phosphorylation profiling of Bcr-Abl-positive chronic myeloid leukemia cells.

C Preisinger, J P Schwarz, O B Bleijerveld, E Corradini, P J Müller, K I Anderson, W Kolch, A Scholten, A J R Heck.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22976128     DOI： 10.1038/leu.2012.243

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  10 in total

1.  Development of a 5-plex SILAC method tuned for the quantitation of tyrosine phosphorylation dynamics.

Authors:  Manuel Tzouros; Sabrina Golling; David Avila; Jens Lamerz; Marco Berrera; Martin Ebeling; Hanno Langen; Angélique Augustin
Journal:  Mol Cell Proteomics       Date:  2013-07-23       Impact factor: 5.911

2.  Quantitative phosphotyrosine profiling of patient-derived xenografts identifies therapeutic targets in pediatric leukemia.

Authors:  Sibasish Dolai; Keith C S Sia; Alissa K Robbins; Ling Zhong; Sue L Heatley; Tiffaney L Vincent; Falko Hochgräfe; Rosemary Sutton; Raushan T Kurmasheva; Tamas Revesz; Deborah L White; Peter J Houghton; Malcolm A Smith; David T Teachey; Roger J Daly; Mark J Raftery; Richard B Lock
Journal:  Cancer Res       Date:  2016-03-09       Impact factor: 12.701

3.  Phosphoproteomics-mediated identification of Fer kinase as a target of mutant Shp2 in Noonan and LEOPARD syndrome.

Authors:  Jeroen Paardekooper Overman; Christian Preisinger; Karin Prummel; Monica Bonetti; Piero Giansanti; Albert Heck; Jeroen den Hertog
Journal:  PLoS One       Date:  2014-09-03       Impact factor: 3.240

4.  Axitinib and sorafenib are potent in tyrosine kinase inhibitor resistant chronic myeloid leukemia cells.

Authors:  Sebastian Halbach; Zehan Hu; Christine Gretzmeier; Julia Ellermann; Franziska U Wöhrle; Jörn Dengjel; Tilman Brummer
Journal:  Cell Commun Signal       Date:  2016-02-24       Impact factor: 5.712

5.  Structural and functional dissection of the DH and PH domains of oncogenic Bcr-Abl tyrosine kinase.

Authors:  Sina Reckel; Charlotte Gehin; Delphine Tardivon; Sandrine Georgeon; Tim Kükenshöner; Frank Löhr; Akiko Koide; Lena Buchner; Alejandro Panjkovich; Aline Reynaud; Sara Pinho; Barbara Gerig; Dmitri Svergun; Florence Pojer; Peter Güntert; Volker Dötsch; Shohei Koide; Anne-Claude Gavin; Oliver Hantschel
Journal:  Nat Commun       Date:  2017-12-13       Impact factor: 14.919

6.  IgG-Independent Co-aggregation of FcεRI and FcγRIIB Results in LYN- and SHIP1-Dependent Tyrosine Phosphorylation of FcγRIIB in Murine Bone Marrow-Derived Mast Cells.

Authors:  Mathias Gast; Christian Preisinger; Falk Nimmerjahn; Michael Huber
Journal:  Front Immunol       Date:  2018-08-27       Impact factor: 7.561

7.  The Giant HECT E3 Ubiquitin Ligase HERC1 Is Aberrantly Expressed in Myeloid Related Disorders and It Is a Novel BCR-ABL1 Binding Partner.

Authors:  Muhammad Shahzad Ali; Cristina Panuzzo; Chiara Calabrese; Alessandro Maglione; Rocco Piazza; Daniela Cilloni; Giuseppe Saglio; Barbara Pergolizzi; Enrico Bracco
Journal:  Cancers (Basel)       Date:  2021-01-19       Impact factor: 6.639

8.  Semi-supervised prediction of SH2-peptide interactions from imbalanced high-throughput data.

Authors:  Kousik Kundu; Fabrizio Costa; Michael Huber; Michael Reth; Rolf Backofen
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

9.  Alterations of Gab2 signalling complexes in imatinib and dasatinib treated chronic myeloid leukaemia cells.

Authors:  Sebastian Halbach; Kristoffer Tg Rigbolt; Franziska U Wöhrle; Britta Diedrich; Christine Gretzmeier; Tilman Brummer; Jörn Dengjel
Journal:  Cell Commun Signal       Date:  2013-04-22       Impact factor: 5.712

10.  Development of a novel method for the quantification of tyrosine 39 phosphorylated α- and β-synuclein in human cerebrospinal fluid.

Authors:  Chan Hyun Na; Gajanan Sathe; Liana S Rosenthal; Abhay R Moghekar; Valina L Dawson; Ted M Dawson; Akhilesh Pandey
Journal:  Clin Proteomics       Date:  2020-05-04       Impact factor: 3.988
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.